What Emerging Class of Agents Should Be Used in Relapsed/Refractory MM Upon Approval? Sagar Lonial, MD, FACP vs. Peter Voorhees, MD vs. Kenneth Anderson, MD #ASH20

29:57

Should Antibodies be a Standard Agent Included in Regimens for First Relapse? Sagar Lonial, MD, FACP vs. Kenneth Anderson, MD #ASH20

21:49

Panel Discussion and Q&A #ASH20

15:32

Transplant vs. No Transplant; Kenneth Anderson vs. Peter Voorhees, MD #ASH20

23:47

Is There Sufficient Data to Include Antibodies in Frontline Regimens? Pieter Sonneveld, MD, PhD vs. Peter Voorhees, MD #ASH20

25:56

Should We be Treating Patients with High-Risk Smoldering MM? Pieter Sonneveld, MD, PhD vs. Peter Voorhees, MD #ASH20

20:39

Nina Shah, MD #HemeWorkshop2020

5:16

Nina Shah talks about differences in tumor microenvironment populations and how stimulatory/inhibotory factors can influence how patients respond to immunotherapy, and new BCMA-targeted therapies for myeloma on the horizon.

Nikhil Munshi, MD; Sagar Lonial, MD, FACP #HemeWorkshop2020

9:04

Nikhil Munshi talks to Sagar Lonial about the use of antibody-drug conjugate to target BCMA in myeloma.

Cesar Rodriguez Valdez, MD; Wake Forest University Comprehensive Cancer Center; 5Live #ASH20

7:20

Key insights from the 2020 Annual Hematology meeting in Multiple Myeloma

Deepu Madduri, MD; Mount Sinai Hospital; 5Live #ASH20

2:03

Key insights from the 2020 Annual Hematology meeting in Multiple Myeloma

Saad Usmani, MD MBA FACP; Levine Cancer Institute/Atrium Health; 5Live #ASH20

5:46

Key insights from the 2020 Annual Hematology meeting in Multiple Myeloma